Key result
Obesity drives metabolic comorbidities via chronic inflammation from adipose tissue dysfunction and gut dysbiosis.
Why the study?
Chronic low-grade inflammation is a key mechanism in the development and persistence of obesity and its metabolic and organ-related complications, but its pathophysiological mechanisms and clinical implications require comprehensive analysis.
Population
Patients with obesity
Design
Review of the literature
Authors
Loading...
Supports viewing obesity as inflammatory; leaves open whether targeting this pathway improves outcomes beyond weight loss.
Recognizing obesity as a chronic inflammatory disease shifts the treatment paradigm towards therapies that restore immunological and metabolic balance, such as GLP-1 receptor agonists.
Kuba et al. (2026) conducted a review in Obesity. Obesity-induced chronic low-grade inflammation was evaluated. Obesity acts as a chronic low-grade inflammatory disease driven by adipose tissue dysfunction and gut dysbiosis, leading to insulin resistance and numerous metabolic comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: